Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Food Archives
Print | Email | Share | Comments (0)

A New Ally Against Impotence


Feb 1, 1997

Now impotence sufferers have another valuable ally. VIVUS Inc. has received clearance from the U.S. Food and Drug Administration (FDA) to market its new product MUSE (Alprostadil), a urethral suppository for the treatment of impotence.

MUSE is based on the concept that medications can be absorbed by the urethra and transported into the surrounding erectile tissues.

Thirty percent of American men between the ages of 40 and 70 are thought to suffer from impotence. The treatments available to them include prosthetic implants, vacuum devices and medications.

MUSE uses a needle-free plastic applicator that is inserted approximately one inch into the urethra, where the medicine is released. The medicine injected is Alprostadil, a synthetic version of Prostaglandin E1, a naturally occurring blood vessel dilator used since 1981 and approved by the FDA for injection in 1995.

"MUSE (Alprostadil) is clearly a very effective, desirable treatment choice," said J. Francois Eid, MD, in a company press release. "(It) offers men and their partners a convenient, discreet treatment that can be easily integrated into a patient's sex life."

Nearly 1,000 patients in the company's study were broken into four groups, consisting of those with vascular disease, those with diabetes, those with abdominal trauma/surgery and those with other organic causes. Seven out of 10 administrations with the MUSE resulted in sexual intercourse.

While the study found no "serious adverse events" due to the product, 0.1 percent of patients reported persistent erections. The most common side-effect was discomfort in use, but only 1 percent of the test subjects dropped out due to pain.

The product is expected to be available by prescription in the United States in early 1997.


Categories: Diabetes, Food, Government & Policy, Medications, Men's Issues, Sexual Issues



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Feb 1, 1997

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.